Peters W
Postgrad Med J. 1973 Aug;49(574):573-83. doi: 10.1136/pgmj.49.574.573.
New antimalarial drugs are required, partly because of the emergence of drug resistant strains of malaria parasites and partly because better compounds are needed to cure relapsing tertian malaria. In reviewing the diverse modes of action of currently used anti-malarials, against a background of the pathogenesis of malaria, attention is drawn to deficiencies in our knowledge. Even less do we understand how the malaria parasite becomes resistant to certain drugs, in particular chloroquine. New approaches to the problem include the application of combinations of existing antimalarials, and the search for new drugs on an unprecedentedly vast scale. Out of over a quarter million compounds that have recently been screened, a handful are now in clinical trial and are showing great promise for the treatment of multiple resistant falciparum malaria. The paper concludes by summarizing current recommendations for the prophylaxis and therapy of malaria due to drug resistant parasites.
新型抗疟药物是必需的，部分原因是疟原虫耐药菌株的出现，部分原因是需要更好的化合物来治愈复发性间日疟。在回顾当前使用的抗疟药的多种作用方式时，以疟疾发病机制为背景，人们注意到我们知识上的不足。我们对疟原虫如何对某些药物，尤其是氯喹产生耐药性了解得更少。解决这个问题的新方法包括应用现有抗疟药的联合用药，以及以前所未有的规模寻找新药。在最近筛选的超过25万种化合物中，有几种目前正在进行临床试验，对治疗多重耐药恶性疟显示出很大的前景。本文最后总结了针对耐药寄生虫引起的疟疾的预防和治疗的当前建议。
